Irritable Bowel Syndrome: Manipulating the Endocannabinoid System As First-Line Treatment

Overview

Journal Front Neurosci

Date 2020 May 7

PMID 32372912

Citations 5

Authors

Viola Brugnatelli

Fabio Turco

Ulderico Freo

Gastone Zanette

Affiliations

Soon will be listed here.

Citing Articles

FMT and TCM to treat diarrhoeal irritable bowel syndrome with induced spleen deficiency syndrome- microbiomic and metabolomic insights.

Tang B, Su C, Wen N, Zhang Q, Chen J, Liu B BMC Microbiol. 2024; 24(1):433.

PMID: 39455910 PMC: 11515126. DOI: 10.1186/s12866-024-03592-y.

Neuro-Gastro-Cannabinology: A Novel Paradigm for Regulating Mood and Digestive Health.

Turco F, Brugnatelli V, Abalo R Med Cannabis Cannabinoids. 2023; 6(1):130-137.

PMID: 37920559 PMC: 10618907. DOI: 10.1159/000534007.

Effects of Cannabidiol Chewing Gum on Perceived Pain and Well-Being of Irritable Bowel Syndrome Patients: A Placebo-Controlled Crossover Exploratory Intervention Study with Symptom-Driven Dosing.

van Orten-Luiten A, de Roos N, Majait S, Witteman B, Witkamp R Cannabis Cannabinoid Res. 2021; 7(4):436-444.

PMID: 33998882 PMC: 9418368. DOI: 10.1089/can.2020.0087.

Cannabinoid Receptors Overexpression in a Rat Model of Irritable Bowel Syndrome (IBS) after Treatment with a Ketogenic Diet.

Gigante I, Tutino V, Russo F, De Nunzio V, Coletta S, Armentano R Int J Mol Sci. 2021; 22(6).

PMID: 33809047 PMC: 7999285. DOI: 10.3390/ijms22062880.

Editorial: Application of Plant Secondary Metabolites to Pain Neuromodulation.

Singla R, Guimaraes A, Zengin G Front Pharmacol. 2021; 11:623399.

PMID: 33519489 PMC: 7841409. DOI: 10.3389/fphar.2020.623399.

References

Izzo A, Sharkey K . Cannabinoids and the gut: new developments and emerging concepts. Pharmacol Ther. 2010; 126(1):21-38. DOI: 10.1016/j.pharmthera.2009.12.005. View

Di Marzo V, Matias I . Endocannabinoid control of food intake and energy balance. Nat Neurosci. 2005; 8(5):585-9. DOI: 10.1038/nn1457. View

Russo E . Clinical Endocannabinoid Deficiency Reconsidered: Current Research Supports the Theory in Migraine, Fibromyalgia, Irritable Bowel, and Other Treatment-Resistant Syndromes. Cannabis Cannabinoid Res. 2017; 1(1):154-165. PMC: 5576607. DOI: 10.1089/can.2016.0009. View

Hohmann A, Suplita 2nd R . Endocannabinoid mechanisms of pain modulation. AAPS J. 2007; 8(4):E693-708. PMC: 2751366. DOI: 10.1208/aapsj080479. View

Izzo A . The cannabinoid CB(2) receptor: a good friend in the gut. Neurogastroenterol Motil. 2007; 19(9):704-8. DOI: 10.1111/j.1365-2982.2007.00977.x. View

Russo E . Clinical endocannabinoid deficiency (CECD): can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions?. Neuro Endocrinol Lett. 2004; 25(1-2):31-9. View

Hong S, Fan J, Kemmerer E, Evans S, Li Y, Wiley J . Reciprocal changes in vanilloid (TRPV1) and endocannabinoid (CB1) receptors contribute to visceral hyperalgesia in the water avoidance stressed rat. Gut. 2008; 58(2):202-10. PMC: 4236191. DOI: 10.1136/gut.2008.157594. View

Holzer P . TRP channels in the digestive system. Curr Pharm Biotechnol. 2010; 12(1):24-34. PMC: 3160477. DOI: 10.2174/138920111793937862. View

Hong S, Zheng G, Wiley J . Epigenetic regulation of genes that modulate chronic stress-induced visceral pain in the peripheral nervous system. Gastroenterology. 2014; 148(1):148-157.e7. PMC: 4274248. DOI: 10.1053/j.gastro.2014.09.032. View

10.

Cluny N, Keenan C, Reimer R, Le Foll B, Sharkey K . Prevention of Diet-Induced Obesity Effects on Body Weight and Gut Microbiota in Mice Treated Chronically with Δ9-Tetrahydrocannabinol. PLoS One. 2015; 10(12):e0144270. PMC: 4669115. DOI: 10.1371/journal.pone.0144270. View

11.

Malik Z, Baik D, Schey R . The role of cannabinoids in regulation of nausea and vomiting, and visceral pain. Curr Gastroenterol Rep. 2015; 17(2):429. DOI: 10.1007/s11894-015-0429-1. View

12.

Pandey S, Kashif S, Youssef M, Sarwal S, Zraik H, Singh R . Endocannabinoid system in irritable bowel syndrome and cannabis as a therapy. Complement Ther Med. 2020; 48:102242. DOI: 10.1016/j.ctim.2019.102242. View

13.

Ahluwalia J, Urban L, Capogna M, Bevan S, Nagy I . Cannabinoid 1 receptors are expressed in nociceptive primary sensory neurons. Neuroscience. 2000; 100(4):685-8. DOI: 10.1016/s0306-4522(00)00389-4. View

14.

Chang L, Sundaresh S, Elliott J, Anton P, Baldi P, Licudine A . Dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis in irritable bowel syndrome. Neurogastroenterol Motil. 2008; 21(2):149-59. PMC: 2745840. DOI: 10.1111/j.1365-2982.2008.01171.x. View

15.

Wouters M, Balemans D, Van Wanrooy S, Dooley J, Cibert-Goton V, Alpizar Y . Histamine Receptor H1-Mediated Sensitization of TRPV1 Mediates Visceral Hypersensitivity and Symptoms in Patients With Irritable Bowel Syndrome. Gastroenterology. 2016; 150(4):875-87.e9. DOI: 10.1053/j.gastro.2015.12.034. View

16.

DiPatrizio N . Endocannabinoids in the Gut. Cannabis Cannabinoid Res. 2016; 1(1):67-77. PMC: 4940133. DOI: 10.1089/can.2016.0001. View

17.

Nicolodi M, SICUTERI F . Fibromyalgia and migraine, two faces of the same mechanism. Serotonin as the common clue for pathogenesis and therapy. Adv Exp Med Biol. 1996; 398:373-9. DOI: 10.1007/978-1-4613-0381-7_58. View

18.

Merat S, Khalili S, Mostajabi P, Ghorbani A, Ansari R, Malekzadeh R . The effect of enteric-coated, delayed-release peppermint oil on irritable bowel syndrome. Dig Dis Sci. 2009; 55(5):1385-90. DOI: 10.1007/s10620-009-0854-9. View

19.

Camilleri M, Kolar G, Vazquez-Roque M, Carlson P, Burton D, Zinsmeister A . Cannabinoid receptor 1 gene and irritable bowel syndrome: phenotype and quantitative traits. Am J Physiol Gastrointest Liver Physiol. 2013; 304(5):G553-60. PMC: 3602676. DOI: 10.1152/ajpgi.00376.2012. View

20.

Ahn E, Kim D, Shin M, Kim H, Kim S, Woo S . PEP-1-PEA-15 protects against toxin-induced neuronal damage in a mouse model of Parkinson's disease. Biochim Biophys Acta. 2014; 1840(6):1686-700. DOI: 10.1016/j.bbagen.2014.01.004. View